|
|
|
|
| LEADER |
02414nam a2200313 u 4500 |
| 001 |
EB000942950 |
| 003 |
EBX01000000000000000736540 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Wilt, Timothy J.
|
| 245 |
0 |
0 |
|a Comparative effectiveness of therapies for clinically localized prostate cancer
|h Elektronische Ressource
|c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Minnesota Evidence-based Practice Center ; investigators, Timothy J. Wilt ... [et al.]
|
| 260 |
|
|
|a [Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2008, 2008]
|
| 300 |
|
|
|a 1 PDF file (1 v. (various pagings
|b ill.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Prostatic Neoplasms / prevention & control
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Risk Assessment
|
| 653 |
|
|
|a Prostatic Neoplasms / therapy
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Minnesota Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness review
|
| 500 |
|
|
|a Title from PDF t.p. (viewed Aug. 30, 2011). - "February 2008.". - "Contract no. 290-02-0009."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK43147
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This report summarizes evidence comparing the relative effectiveness and safety of treatment options for clinically localized prostate cancer. The report addresses the following questions: 1) What are the comparative risks, benefits, short- and long-term outcomes of therapies for clinically localized prostate cancer? 2) How do specific patient characteristics, e.g., age, race/ethnicity, presence or absence of comorbid illness, preferences (e.g., tradeoff of treatment-related adverse effects vs. potential for disease progression), affect the outcomes of these therapies, overall and differentially? 3) How do provider/hospital characteristics affect outcomes overall and differentially (e.g., geographic region and volume)? 4) How do tumor characteristics, e.g., Gleason score, tumor volume, screen vs. clinically detected tumors, affect the outcomes of these therapies, overall and differentially?
|